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Abstract 
Background: The p.E318K variant of the Melanocyte Inducing Transcription Factor (MITF) has been implicated in 
genetic predisposition to melanoma as an intermediate penetrance allele. However, the impact of this variant on clin-
ico-phenotypic, as well as on dermoscopic patterns features of affected patients is not entirely defined. The purpose 
of our study was to assess the association between the p.E318K germline variant and clinic-phenotypical features of 
MITF+ compared to non-carriers (MITF−), including dermoscopic findings of melanomas and dysplastic nevi.
Methods: we retrospectively analyzed a consecutive series of 1386 patients recruited between 2000 and 2017 who 
underwent genetic testing for CDKN2A, CDK4, MC1R and MITF germline variants in our laboratory for diagnostic/
research purposes. The patients were probands of melanoma-prone families and apparently sporadic single or multi-
ple primary melanoma patients. For all, we collected clinical, pathological information and dermoscopic images of the 
histopathologically diagnosed melanomas and dysplastic nevi, when available.
Results: After excluding patients positive for CDKN2A/CDK4 pathogenic variants and those affected by non-cutane-
ous melanomas, our study cohort comprised 984 cutaneous melanoma patients, 22 MITF+ and 962 MITF−. MITF+ 
were more likely to develop dysplastic nevi and multiple primary melanomas. Nodular melanoma was more common 
in MITF+ patients (32% compared to 19% in MITF−). MITF+ patients showed more frequently dysplastic nevi and 
melanomas with uncommon dermoscopic patterns (unspecific), as opposed to MITF− patients, whose most preva-
lent pattern was the multicomponent.
Conclusions: MITF+ patients tend to develop melanomas and dysplastic nevi with histopathological features, fre-
quency and dermoscopic patterns often different from those prevalent in MITF− patients. Our results emphasize the 
importance of melanoma prevention programs for MITF+ patients, including dermatologic surveillance with digital 
follow-up.
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Background
Malignant melanoma is a potentially lethal tumor result-
ing from the malignant transformation of melanocytes. 
A recent meta-analysis showed that 70.9% of melanomas 
likely arises de novo from melanocytes located in previ-
ously normal skin, mucous membranes or other sites 
(eye, inner ear, gastrointestinal system) and 29.1% arises 
from melanocytes in pre-existing lesions (nevi or dys-
plastic nevi). Ultraviolet light, especially indoor tanning, 
exposure is a known carcinogen clearly correlated with 
melanoma.
The worldwide incidence of melanoma is increasing 
and it is estimated to further increase mainly due to the 
lengthening of the human lifetime and the aging of pop-
ulation: currently, the lifetime risk of developing mela-
noma is 1 in 63 in the United States and in other Western 
countries.
Along with lifestyle, genetic risk factors are significant 
conditions contributing to melanoma development [1, 2].
A number of novel candidate melanoma predisposi-
tion genes, in addition to the well know high penetrance 
genes such as Cyclin Dependent Kinase Inhibitor 2A 
(CDKN2A), Cyclin-Dependent Kinase 4 (CDK4) and 
low-penetrance genes such as Melanocortin 1 Recep-
tor (MC1R) have been uncovered in the last few years. 
These include genes involved in DNA replication (tel-
omere maintenance) or repair, such as Telomere Reverse 
Transcriptase (TERT), Protection of Telomeres 1 (POT1), 
Adrenocortical Dysplasia (ACD), Telomeric Repeat-
Binding Factor-2 (TERF2) Interacting Protein (TERF2IP), 
and Breast Cancer Gene 1 (BRCA1)-Associated Protein 
1 (BAP1). Moreover, the p.E318K variant of the Mel-
anocyte Inducing Transcription Factor (MITF) gene has 
recently been implicated in cancer predisposition [3–5]. 
The groups of Bertolotto [6] and Yokoyama [7] indepen-
dently identified the p.E318K variant and categorized 
MITF as an intermediate penetrance melanoma suscep-
tibility gene. Indeed, patients carrier of this germline 
variant have a more than fivefold increased risk of devel-
oping melanoma (both familial and sporadic), renal cell 
carcinoma (RCC) or both cancers than non-carriers. The 
p.E318K variant has also been associated with increased 
nevus count, non-blue eye color and developing of mul-
tiple primary melanoma [7]. MITF is the ‘master regu-
lator’ of differentiation, survival and proliferation of 
normal melanocytes and is critical in controlling prolif-
eration, migration and invasion of melanoma cells [8]. 
It has been demonstrated that MITF acts not only as a 
master transcription factor, involved in cell cycle regu-
lation, but also as a transcriptional repressor [9]. The 
p.E318K variant alters the SUMOylation of MITF thus 
impairing MITF inhibitory activity [6, 7]. More spe-
cifically, in normal cells under normoxia, the small 
ubiquitin-like modifier (SUMO) proteins, bind MITF 
decreasing the transcription of the hypoxia inducible 
factor 1 A (HIF1A). In addition, HIF1A is hydroxylated 
for subsequent proteasome mediated degradation of the 
cells. Under hypoxia, SUMOs are released, allowing the 
transcription of HIF1A and anaerobic metabolism or 
glycolysis. The p.E318K variant of MITF in melanoma 
and renal carcinoma cells severely impaired SUMOyla-
tion of MITF, resulting in an increased transcription of 
HIF1A and other genes compared to wild-type MITF. 
Even under normoxic conditions, the p.E318K variant 
allows cancer cells to activate a pseudohypoxic response 
or aerobic glycolysis and this “Warburg effect” predispose 
to cancer progression and metastasis [10].
Due to the above-mentioned links with melanoma and 
kidney cancer susceptibility, current research is focusing 
on the relationship between p.E318K and the clinico-
phenotypic features of individuals carrying this variant 
[9, 11–16]. However, current literature on dermoscopic 
features of nevi and melanomas in these patients is still 
limited, and predisposition to non-melanoma cancers 
according to MITF germline status needs to be further 
investigated [11, 14, 16].
The aim of the present work was to retrospectively 
study genotype–phenotype correlations in melanoma 
patients carrier of the p. E318K MITF germline variant 
(MITF+), compared with non-carrier melanoma patients 
(MITF−). Among the analyzed phenotypic features, we 
included dermoscopic findings of histopathologically 
diagnosed dysplastic nevi (DN) and cutaneous melano-
mas in MITF+ and MITF−.
Methods
Patients characteristics
Between 2000 and 2017 we recruited a consecutive series 
of 1386 patients. This cohort included probands of mel-
anoma-prone families and apparently sporadic patients 
diagnosed with multiple primary melanomas who under-
went genetic testing for diagnostic or research purposes, 
as well as apparently sporadic patients with melanoma, 
tested for research purposes only. All patients, except 
one case already characterized for germline status, were 
subjected to genetic testing for CDKN2A, CDK4, MC1R 
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and MITF germline variants in our laboratory. For all 
patients, we collected and stored clinical and pathologi-
cal information. In addition, when available, we collected 
dermoscopic images of the histopathologically diagnosed 
DN and cutaneous melanomas.
Indeed, the histopathological diagnosis of DN is based 
on the presence of both of the two major criteria (pro-
liferation of atypical melanocytes extending beyond the 
dermal component; atypical melanocytes arranged in 
a lentiginous/epithelioid-cell pattern) and at least two 
minor criteria (lamellar/eosinophilic fibrosis; neovascu-
larization; inflammatory response; fusion of rete ridges) 
[17].
For 667 of the patients included in this study, molecu-
lar and, partly, clinical information have been previously 
described [13].
Collection of clinical, pathological and dermoscopic data
Clinical information were collected through a question-
naire, administered by a trained interviewer, and included 
phenotype and personal/family history of melanomas 
and other tumors, as previously described [18, 19]. Either 
clinical records or local cancer registry data were used to 
collect pathological information, including tumor histo-
logical type and staging according to the American Joint 
Committee on Cancer (AJCC)’s TNM staging system [20, 
21]. For both MITF+ and MITF− patients, the following 
phenotypical and clinico-pathological features were stud-
ied: phototype, freckles, hair and eye color, total number 
of nevi with diameter > 2 mm, number of histopathologi-
cally diagnosed DN and number of histopathologically 
diagnosed cutaneous melanomas. For first diagnosed 
melanomas, we also gathered information on age at diag-
nosis, anatomical site, histotype, Breslow thickness (mm), 
sentinel lymph node and stage.
Dermoscopic images of lesions clinically suggestive of 
melanomas were collected through the FotoFinder der-
moscope Medicam 1000 (FotoFinder Systems GmbH, 
Bavaria, Germany) during dermatologic visits performed 
for screening (first visit) or for follow-up at the Derma-
tologic Clinic of the San Martino Hospital (Genoa, Italy) 
and at the Dermatologic outpatient clinic, Division of 
Oncology, Centro di Riferimento Oncologico, Aviano 
National Cancer Institute (Aviano, Italy).
The analysis of global dermoscopic pattern was ret-
rospectively performed on all available dermoscopic 
images of non-acral lesions according to the dermo-
scopic classification of acquired melanocytic nevi, as 
follows: reticular, globular, homogenous, multicompo-
nent, reticular-globular, reticular-homogenous, globu-
lar-homogenous and unspecific pattern. This latter was 
defined as a pattern lacking specific features related to 
a melanocytic or non melanocytic lesions. Conversely, 
the following dermoscopic patterns were considered to 
assess acral melanocytic lesions: parallel furrow, parallel 
ridge, lattice-like, fibrillary [22, 23]. All the dermoscopic 
images were evaluated by a panel of three independent 
observers; the dermoscopic features were scored based 
on the agreement of two observer (G.C. and F.D.) and in 
case of disagreement between the two observers, a third 
observer (M.A.P.) was consulted. The evaluation of the 
dermoscopic criteria was made when 3/3 or 2/3 observ-
ers agreed.
Molecular analysis
All patients provided a blood sample from which we 
extracted genomic DNA. Purified DNA samples were 
then amplified by conventional polymerase chain reac-
tion (PCR) and analyzed by Sanger sequencing to assess 
the germline status of CDKN2A, CDK4, MC1R and 
MITF. Samples processing and analysis were performed 
as previously described [24, 25].
Patients selection
From the melanoma cohort, we excluded the patients 
lacking information on germline status and tumor stage, 
as well as those with non-cutaneous melanoma (ocular 
and mucosal melanomas). Moreover, to avoid confound-
ing effects by CDKN2A and CDK4, patients with concur-
rent CDKN2A and CDK4 pathogenic variants were also 
excluded from this study. Subsequently, we gathered 
MITF+ and MITF− patients into two separate study 
groups. All patients signed a written informed consent 
according to local ethics committee approved protocol 
prior to enrolment in the study.
Statistical analysis
To assess the difference of a numerical variable between 
the two study groups (age at diagnosis, Breslow thick-
ness, number of melanomas diagnosed, total number 
of nevi, number of dysplastic nevi) we used the Mann–
Whitney U test.
To assess the association between MITF+ germline 
status and a categorical variable (hair-eye color, famil-
ial status, sentinel node status, familiarity for pancreatic 
and kidney cancer, site and histotype of first melanoma, 
dermoscopic pattern of DN and melanomas grouped 
together, MC1R germline status, histopathologically 
diagnosed melanomas and DN analyzed as a dichoto-
mous variable), we used the Fisher’s exact test.
Kruskal–Wallis test was used to analyze the association 
between MITF germline status and an ordinal variable 
(phototype, freckles, tumor stage and number of nevi 
grouped in three categories).
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Results
After excluding 246 patients with missing information 
on MITF mutational status, 133 patients either positive 
for CDKN2A/CDK4 pathogenic variants or with miss-
ing information on CDKN2A/CDK4 germline status, and 
23 patients affected by ocular or mucosal melanomas, 
our study cohort comprised 984 cutaneous melanoma 
patients, 22 MITF+ and 962 MITF− (Fig. 1). Of the 22 
MITF+ patients, 5 had a positive family history of mel-
anoma, whereas the remaining 17 were apparently spo-
radic cases. Overall, 6 patients, all apparently sporadic 
cases, developed multiple melanomas. Even though the 
overall prevalence of the MITF p.E318K variant was 2.2% 
(22 of 984), MITF p.E318K was more common among 
N=1007
MITF germline status missing 
(N=246)
CDKN2A/CDK4-positive or 
missing germline 
status(N=133)
Ocular (N=15)
Mucosal (N=8)
N=984
962 MITF-22 MITF+ 
N=1140
Total patients N= 1386
Fig. 1 Patients selection workflow
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multiple primary melanoma (MPM) patients (5% com-
pared to 2% in single melanoma patients). All MPM 
MITF+ patients were sporadic, whereas among single 
primary melanoma (SPM) patients MITF p.E318K rate 
was similar in familial and sporadic subgroups.
The distribution of MC1R variants did not significantly 
differ between the two study groups (p = 0.45, Table  1). 
In the MITF+ group, two patients had amelanotic/
hypomelanotic melanomas; both patients carried one 
red-hair-color (RHC) MC1R variant (R169W, R142H).
Clinico‑pathological features
The two study groups displayed significant differences 
with regards to: total number of nevi, number of histo-
pathologically diagnosed DN and melanomas, histotype 
of first melanoma and family history of kidney can-
cer (Table  1). More specifically, MITF+ patients had, 
in median, a higher total number of nevi compared to 
MITF− patients: 28% of MITF+ patients had more than 
50 nevi, compared to 19% of MITF− patients (p = 0.04).
The number of melanomas removed was higher in 
MITF+ compared to MITF− negative patients: 27% of 
the MITF+ patients have removed more than 2 melano-
mas versus 11% of the MITF− patients (p = 0.03).
Patients with at least one histologically diagnosed DN 
were more frequent in the MITF+ group, (50% vs. 10% 
in the MITF− group, p < 0.001) with a higher median DN 
removal compared to MITF− (median = 0.5, IQR = 0–1 
and median = 0, IQR = 0–0, respectively; p < 0.001).
Concerning the histotype of first melanoma, MITF+ 
patients showed a higher rate of nodular melanomas than 
MITF− patients (32% and 19%, respectively, p = 0.04).
Patients with MPM were more frequently MITF+ 
(27% compared to 11% of MITF− patients, p = 0.03). A 
positive family history for kidney cancer was more fre-
quent among MITF+ patients (18% versus 5% of MITF− 
patients; p = 0.01).
We also compared phenotypical features between the 
MITF+ and MITF− patients, and no significant differ-
ences were found as regards phototype, hair and eyes 
color, freckles, age at first melanoma diagnosis, anatomi-
cal site, Breslow thickness, sentinel lymph node, stage of 
first melanoma and family history of melanoma or pan-
creatic cancer (Table 1).
Dermoscopic features
The dermoscopic patterns of 23 lesions (including DN 
and melanomas) belonging to four MITF+ patients were 
compared with those of 47 lesions (DN and melanomas) 
belonging to 37 MITF− patients (Table 2).
When dermoscopically evaluating only melanomas, 
nine lesions belonging to three MITF+ were compared 
with those of 23 lesions belonging to 22 MITF− (Table 3).
Of the 23 dermoscopic images from the four MITF+ 
patients, seven melanomas (four with structureless, two 
with multicomponent and one with globular-homoge-
nous pattern) and ten DN (two with homogenous, four 
with reticular-homogenous and four with globular-
homogenous pattern) belonged to one single patients. 
This patient actually developed 10 melanomas, only 7 of 
which had dermoscopic images.
When we analyzed the global patterns of DN and mela-
nomas, grouped together as a single variable, the unspe-
cific, globular-homogenous and reticular-homogenous 
patterns were more frequent in MITF+ compared to 
MITF− patients; conversely, the multicomponent pattern 
was more common in MITF− than in MITF+ patients, 
as shown in Table  2 (p < 0.001). We could not perform 
the same analysis on a melanoma-only subset because 
of the small resulting sample size. However, as regards 
melanomas, the frequency of global dermoscopic pat-
terns among the two study groups is reported in Table 3. 
The unspecific pattern was found more frequently in 
melanomas of MITF+ (45% of the lesions) than in those 
of MITF− patients (13% of the lesions), while the mul-
ticomponent pattern was seen more frequently among 
melanomas of MITF− (65% of the lesions) than those of 
MITF+ patients (22%) (Fig. 2). Taking into account that 
a considerable number of melanocitic lesions belonged 
to the same patient, we performed again the analy-
sis excluding this outlier patient, to reduce the risk that 
such a relevant number of non-independent samples 
could bias our results. Even without the outlier patient, 
melanocytic lesions in MITF+ and MITF− patients 
showed a different distribution of dermoscopic patterns 
(p = 0.001). Namely, the unspecific was the most frequent 
dermoscopic pattern found in DN/melanomas of MITF+ 
patients (40%, as opposed to 9% in MITF− lesions). Con-
versely, the multicomponent and the reticular-globular 
patterns (47% and 28% respectively in MITF− lesions) 
were absent in MITF+ lesions.
Discussion
In our study cohort, the prevalence of the p.E318K ger-
mline variant in CDKN2A/CDK4-negative patients was 
2.2%, slightly higher than we previously reported in a 
smaller series of melanoma patients (1.8%) [13], but in 
line with Spanish (1.9%) [14], French (2.8%) [6], Austral-
ian (3.4–3.6%) [16] and American (2.8%) [12] studies.
Considering that the p.E318K variant is not common 
in melanoma patients, attempts to determine its effects 
on MITF+ patients’ phenotypical features and cancer 
predisposition are generally limited by sample size. To 
our best knowledge, the present study describes the larg-
est cohort of MITF+ patients reported to date from a 
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Table 1 Clinical, pathological and molecular characteristics of the study groups
N MITF+ N (%) MITF− N (%) ORa Lower CI Upper CI p‑value
Phototype 927 I 0 (0) 52 (6) 0.27
II 15 (75) 478 (53)
III 5 (25) 353 (39)
IV 0 (0) 24 (3)
Freckles 349 None 8 (4) 77 (23) 0.37
Rare 4 (2) 126 (38)
Few 7 (35) 89 (27)
Many 1 (5) 37 (11)
Hair color 932 Albino 0 (0) 1 (0) 0.06
Red 1 (5) 49 (5)
Blond 9 (43) 201 (22)
Blond_red 0 (0) 9 (1)
Brown 7 (33) 565 (62)
Black 4 (19) 86 (9)
Eye color 931 Light blue 7 (37) 214 (23) 0.50
Blue 1 (5) 38 (4)
Green 2 (11) 98 (11)
Grey 0 (0) 21 (2)
Light brown 1 (5) 206 (23)
Dark brown 8 (42) 324 (36)
Black 0 (0) 5 (1)
Hazel 0 (0) 6 (1)
Number of nevi 492 < 10 3 (17) 200 (42) 0.04
10–50 10 (55) 185 (39)
> 50 5 (28) 89 (19)
Histologically diagnosed Dysplastic nevi 866 Median (IQR) 0 (0–1) 0 (0–0) < 0.001
0 10 (50) 769 (91) 9.93 3.59 27.53 < 0.001
1+ 10 (50) 77 (9)
Familial 984 Spo 17 (77) 833 (87) 1.9 0.54 5.48 0.21
Fam 5 (23) 129 (13)
Age at first melanoma 858 Median (IQR) 44 (32.25–58.75) 49 (38.99–61.71) 0.20
N. of melanomas removed 983 Median (IQR) 1 (1–1.75) 1 (1–1) 0.02
1 16 (73) 855 (89) 3.02 0.95 8.35 0.03
2+ 6 (27) 106 (11)
Breslow mm 930 Median (IQR) 1 (0.6–2.025) 1 (0.35–1.765) 0.22
Sentinel node 337 Neg 6 (27) 266 (28) 1.41 0.14 8.1 0.65
Pos 2 (9) 63 (7)
Stage 771 IS 2 (17) 122 (16) 0.65
I 8 (67) 473 (62)
II 2 (17) 75 (10)
III 0 (0) 56 (7)
IV 0 (0) 33 (4)
Pancreatic cancer in family 972 No 19 (86) 901 (94) 2.90 0.53 10.35 0.11
Yes 3 (14) 49 (5)
Kidney cancer in family 971 No 18 (82) 910 (95) 5.17 1.21 16.74 0.01
Yes 4 (18) 39 (5)
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dermoscopic point of view (DN and melanomas), in addi-
tion to a genetic, clinical, and pathological perspective.
Concerning the histotype of the first diagnosed mela-
noma, we validated the association between the p.E318K 
variant and the nodular subtype previously reported by 
our group [13]. Indeed, seven out of 22 p.E318K patients 
(32%) developed a first melanoma with nodular histotype, 
a significantly higher percentage than the one observed 
in MITF− patients (16%). Our results differ from those 
of previous studies by other groups, which did not find 
significant associations of p.E318K with pathological fea-
tures, possibly due to underpowered study samples [14, 
16].
However, Potrony and colleagues reported that dur-
ing 10 years of dermatological surveillance of patients at 
high risk of melanoma, the only two fast-growing mela-
nomas (growth rate greater than 0.4  mm per month) 
were diagnosed in MITF+ patients. Of these two lesions, 
one was a nodular melanoma and the other one was a 
Significant p-values are italicized
N = number of patients, % = percentage of patients, OR = odds ratio, lower CI = lower confidence interval limit, upper CI = upper confidence interval limit, IQR = inter-
quartile range, Spo = sporadic, Fam = familial, Neg = negative, Pos = positive, SSM = superficial spreading melanoma, IS = in situ melanoma, R = MC1R red hair color 
variant, r = MC1R non-red hair color variant
a Odds that the outcome occurs in the MITF+ group compared to the odds of the outcome occurring in the MITF− group
Table 1 (continued)
N MITF+ N (%) MITF− N (%) ORa Lower CI Upper CI p‑value
Site of first melanoma 943 Head and neck 1 (5) 74 (8) 0.27
Trunk 8 (40) 464 (50)
Arms 6 (30) 125 (14)
Legs 5 (25) 260 (28)
Histotype of first melanoma 722 Acral 2 (9) 11 (2) 0.04
Lentigo maligna 0 (0) 36 (5)
Nodular 7 (32) 132 (19)
SSM 13 (59) 454 (64)
Other 0 (0) 67 (10)
MC1R 576 –/– 6 (30) 165 (30) 0.45
r/– 4 (20) 158 (28)
r/r 2 (10) 24 (4)
R/– 6 (30) 111 (21)
R/r 1 (5) 74 (13)
R/R 1 (5) 24 (4)
Table 2 Dermoscopic patterns of  MITF + and MITF− 
dysplastic nevi and cutaneous melanomas
Significant p-values are italicized
N = number of dysplastic nevi/melanomas; % = percentage of dysplastic nevi/
melanomas
Dermoscopic pattern MITF+ MITF− p‑value
N % N %
Structureless 6 26 4 8 < 0.001
Reticular 1 4 1 2
Globular 0 0 3 6
Homogeneous 2 9 0 0
Globular-homogenous 5 22 2 5
Reticular-homogenous 6 26 3 6
Reticular-globular 0 0 12 26
Multicomponent 2 9 22 47
Parallel ridges (or other patterns 
typical of acral melanoma)
1 4 0 0
Total 23 100 47 100
Table 3 Dermoscopic patterns of  MITF+ and  MITF− 
cutaneous melanomas
N = number of melanomas; % = percentage of melanomas
Dermoscopic pattern MITF+ MITF−
N % N %
Structureless 4 45 3 13
Reticular 1 11 0 0
Globular 0 0 2 9
Homogeneous 0 0 0 0
Globular-homogenous 1 11 1 4
Reticular-homogenous 0 0 0 0
Reticular-globular 0 0 2 9
Multicomponent 2 22 15 65
Parallel ridges (or other patterns 
typical of acral melanoma)
1 11 0 0
Total 9 100 23 100
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superficial spreading melanoma (SSM) [14]. However, 
in our MITF+ study group, all nodular melanomas were 
first diagnosed melanomas, identified during dermato-
logical screening with digital follow-up or clinical exami-
nation. Conversely, all subsequent melanomas diagnosed 
in our MITF+ cohort during dermatological follow-
up were SSM, and Breslow thickness of melanomas in 
patients with MPM was always lower than that of the 
preceding ones, except for one patient, possibly reflect-
ing the intensive dermatological follow-up after the first 
melanoma diagnosis. However, further investigations 
with larger series of patients are needed to confirm the 
association between the p.E318K variant and nodular-
type melanoma, and to study the prognostic role of this 
variant.
Concerning the role of the p.E318K variant in the 
predisposition to tumors other than melanoma, we 
confirm the association with renal cell carcinoma 
(RCC) previously described [6, 7, 13–15]. The associa-
tion with pancreatic cancer we previously observed in 
a smaller series of patients [13] was not confirmed here, 
and therefore remains to be further explored. Although 
none of our p.E318K patients developed RCC, 18% of 
them reported a positive family history, as opposed to 
4% of MITF− patients. Apart from melanoma, the most 
frequent tumor in MITF+ patients was basal cell carci-
noma (14% of the patients), in line with previous data 
reported by Potrony et al. [14].
The finding that MITF+ p.E318K was associated 
with a higher number of histopathologically confirmed 
DN in our cohort was never reported to date, differ-
ently from CDKN2A variants, whose possible role in 
influencing the development of dysplastic melanocytic 
lesions has already been described [26, 27].
Our study confirms that MITF+ patients have an 
increased risk of developing multiple melanomas 
and a higher total nevi count compared to MITF− 
patients, as previously reported [6, 7, 13, 14]. Indeed, 
28% of MITF+ patients in our cohort had more than 
50 nevi with > 2  mm diameter, ascompared to 19% of 
MITF− patients. Similarly, previous studies reported 
high nevi counts in MITF+ patients, corroborating the 
Fig. 2 a Clinical and b dermoscopic images of a superficial spreading melanoma of the right thigh with an unspecific dermoscopic pattern in a 
MITF+ patient; this patient also carries one RHC variant (R142H) of MC1R that could be responsible for the hypomelanotic aspect of this lesion; c 
clinical and d dermoscopic images of a superficial spreading melanoma of the left shoulder with a multicomponent pattern in a MITF− patient
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hypothesis that MITF is involved in nevogenesis [11, 
14, 16].
Of course, as MITF p.E318K is considered an inter-
mediate penetrance allele, the possibility that other 
additional gene’s effects may have affected our results 
cannot be completely ruled out. However, patients 
with CDKN2A pathogenic variants were excluded from 
this study, in order to avoid a confounding effect by 
this gene. Moreover, MC1R variants, which influence 
phototype and are associated with melanoma risk [19, 
28], had a similar distribution in the two study groups, 
therefore not affecting our analyses. MC1R RHC vari-
ants have also been associated with the likelihood of 
developing amelanotic/hypomelanotic melanomas [29]. 
In our cohort, both MITF+ patients with amelanotic/
hypomelanotic melanomas carried one RHC variants. 
However, due to the retrospective nature of this study, 
standardized information on pigmentation was not 
available, and therefore we could not assess the impact 
of RHC variants on melanoma pigmentation according 
to MITF germline status.
Although dermoscopic patterns of melanocytic nevi 
in MITF+ and MITF− patients have already been 
reported [11, 14, 16], our study is the first to assess 
the dermoscopic characterization of DN and melano-
mas in MITF+ patients compared to MITF− patients. 
Previous studies [11, 14, 16] found that the predomi-
nant dermoscopic pattern of nevi was the reticular 
one, both in MITF+ and in MITF− patients. Moreo-
ver, Sturm et al. reported that the frequency of globu-
lar nevi was greater in MITF+ patients, albeit not 
significant [16]. In DN and melanomas of our series of 
MITF+ patients, we found 3 prevalent dermoscopic 
patterns: unspecific, globular-homogeneous and retic-
ular-homogeneous. The unspecific pattern was defined 
as devoid of structures or with too few structures to 
identify a pattern, except for the presence of blood 
vessels. This latter pattern is most frequently found in 
amelanotic/hypomelanotic melanocytic lesions includ-
ing amelanotic/hypomelanotic nodular melanomas 
where it can be associated with polymorphous atypical 
vessels [30].
While the reticular pattern is suggestive of photoin-
duced nevogenesis, the globular-homogeneous one, 
with globules at the periphery of the lesion, expression 
of lesion growth, suggests that p.E318K variant may 
also act to force the continuous growth of the nevi/mel-
anomas [31].
Considering only melanomas, the prevalent pattern 
among the MITF+ patients was the unspecific one, a 
finding that has never been associated with the MITF+ 
variant to date.
Conversely, the multicomponent pattern was prevalent 
among the MITF− patients, as already reported in the 
literature [32, 33].
Noteworthy, as a rule, all lesions with unspecific pat-
terns should be biopsied, also in the context of lesions 
clinically appearing benign, to avoid missing melanomas 
[23].
Therefore, the detection of this pattern in MITF+ 
patients should alert dermatologist raising the level of 
suspicion of malignancy.
Since among the 22 MITF+ patients one patient devel-
oped 10 melanomas (of which 7 dermoscopic images 
were available), and the different distribution of clinico-
pathological-dermoscopic features between the two 
groups could have been influenced by this single patient, 
we repeated the analysis excluding this patient. Even 
though the observed patterns were actually influenced 
by this patient, the unspecific pattern remained preva-
lent in MITF+ patients and the association remained 
significant. Dermoscopically, the most common patterns 
of DN and melanomas (multicomponent, reticular-glob-
ular) were almost absent in MITF+ patients, while the 
multicomponent was the most frequent pattern among 
MITF− patients.
The major limitation in this study is the small number 
of images included for assessment of dermoscopic pat-
tern in relation to MITF variant which may influence the 
reliability of these results (only 23 dermoscopic images 
belonging to four MITF+ patients were available).
Conclusions
Besides confirming previous results on the association of 
the p.E318K variant with high number of nevi (> 50 units) 
and higher risk of melanoma and kidney cancers com-
pared to MITF− patients, our study adds the finding that 
MITF+ patients have a higher risk of developing DN 
than MITF− patients. This result underlines the neces-
sity for MITF+ patients to follow melanoma prevention 
programs, including dermatologic surveillance with digi-
tal follow-up.
In MITF+ patients, any melanocytic lesion with a 
dermoscopic pattern that digresses from the most com-
monly dermoscopic patterns reported among the MITF− 
patients, such as multicomponent and reticular-globular 
patterns, should be examined with caution to avoid miss-
ing melanomas that are devoid of structures.
Further studies through an international collaborative 
effort are crucial to increase the sample size and validate 
these findings.
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